Abstract
Elderly patients are often undertreated relative to younger patients in clinical practice. Pem is efficacious as a first-line, second-line, and maintenance treatment for advanced NS NSCLC. Analysis of individual trials in first-line (JMDB) and maintenance (JMEN, PARAMOUNT) settings showed comparable survival (favoring pem over comparators) and toxicity profiles of pem in elderly and nonelderly subgroups. Now, a meta-analysis is presented to give an integrated review of the impact of age on pem efficacy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
